Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : 'Likely link' between rare heart inflammation and Pfizer, Moderna vaccines -CDC advisers

06/23/2021 | 12:02pm EDT

June 23 (Reuters) - Rare cases of heart inflammation in adolescents and young adults is likely linked to vaccination with the Pfizer/BioNTech and Moderna COVID-19 shots, a group of doctors advising the U.S. Centers for Disease Control and Prevention (CDC) said in a presentation released on Wednesday.

The COVID-19 Vaccine Safety Technical (VaST) Work Group said in their report that the risk of myocarditis or pericarditis following vaccination with the mRNA-based shots in adolescents and young adults is notably higher after the second dose and in males.

The CDC said in another report that the patients with heart inflammation following vaccination generally recover from the symptoms and do well.

The Advisory Committee on Immunization Practices (ACIP) is meeting on Wednesday to assess the possibility of a link between the heart condition and the mRNA vaccines. VaST is a sub-group of ACIP.

The CDC has been investigating cases of heart inflammation mainly in young men for several months. The Israeli health ministry earlier this month said it saw a possible link between such cases and Pfizer's COVID-19 vaccine.

The CDC earlier this month said it was still evaluating the risk from the condition and did not confirm a causal relationship between the vaccines and the heart issue.

The agency, however, said a higher-than-expected number of young men have experienced heart inflammation after their second dose of the mRNA COVID-19 shots, with more than half the cases reported in people between the ages of 12 and 24.

Dr. Tom Shimabukuro, deputy director of the CDC's Immunization Safety Office, said in a presentation that data from one of the agency's safety monitoring systems - Vaccine Safety Datalink (VSD) – suggests a rate of 12.6 cases per million in the three weeks after the second shot in 12- to 39-year-olds.

ACIP will discuss the benefits of the mRNA vaccines versus the potential risk to adolescents and young adults from the heart condition, according to the agency's agenda. https://www.cdc.gov/vaccines/acip/meetings/downloads/agenda-archive/agenda-2021-06-23-508.pdf

Although health officials in Israel have determined that there is likely a link between vaccination and the heart inflammation, concerns about the more infectious Delta coronavirus variant have prompted the country to urge 12-to 15-year olds get vaccinated.

Pfizer, whose vaccine has been authorized for use in Americans as young as 12, previously said it had not observed a higher rate of heart inflammation than would normally be expected in the general population.

Moderna had said it could not identify a causal association with the heart inflammation cases and its vaccine.

Over 138 million Americans have so far been fully vaccinated with one of the two mRNA vaccines, according to CDC data as of Monday. (Reporting by Michael Erman in New Jersey and Manojna Maddipatla in Bengaluru; Editing by Bill Berkrot)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 7.84% 348.83 Delayed Quote.209.64%
PFIZER, INC. 0.51% 41.68 Delayed Quote.12.66%
All news about MODERNA, INC.
05:02pMODERNA : U.S. administers 340.4 mln doses of COVID-19 vaccines
04:29pMODERNA : U.S. CDC Says Delivered 393,929,955 Doses Of Covid-19 Vaccine As Of Ju..
02:10pRelaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
12:55pEuropean Stocks Rally After Dovish ECB Comments, Surge in PMI Services and Ou..
11:14aPFIZER : Governors pin hopes on full vaccine approval as cases climb
09:51aMODERNA : COVID-19 Vaccine Gets Positive Opinion From European Medicines Agency ..
09:40aMODERNA : COVID-19 Vaccine Gets Positive EMA Panel Opinion for Use in Adolescent..
09:07aMODERNA : EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Posit..
07:15aMODERNA : Announces New Supply Agreement with Taiwan for 20 Million Doses of Mod..
05:23aLONZA : Contemplates Acquisitions to Boost Booming Vaccine Manufacturing Busines..
More news
Financials (USD)
Sales 2021 19 117 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 13,8x
Yield 2021 -
Capitalization 140 B 140 B -
EV / Sales 2021 6,70x
EV / Sales 2022 7,51x
Nbr of Employees 1 300
Free-Float 90,3%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 348,83 $
Average target price 179,20 $
Spread / Average Target -48,6%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.209.64%88 312
LONZA GROUP AG19.02%53 538
CELLTRION, INC.-25.21%32 170
SEAGEN INC.-18.16%28 525